Shiloh
Editor, Senior Moderator
Source: http://www.voanews.com/content/dengue-fever-vaccine/1590524.html
Dengue Fever Vaccine Trials Clear First Hurdle
Jessica Berman
January 24, 2013
Human trials of an experimental dengue fever vaccine have just concluded, and the experimental compound looks promising in offering protection against the complex mosquito-borne illness that afflicts millions of people living in tropical and sub-tropical regions...
...
The U.S. government-funded trial was small, involving 112 healthy men and women between the ages of 18 and 50. The purpose was to see whether the experimental vaccine, made up of live but weakened viruses, was both safe and stimulated an antibody response against all four dengue types.
Researchers at Johns Hopkins School of Public Health in Baltimore, Maryland formulated four different versions of the combination vaccine, and tested a separate vaccine in each of four groups of 20 study participants. All of the dengue vaccines produced an antibody response. But one experimental compound, called TV003, induced an immune response against all four dengue viruses in 45 percent of participants. And an immune response to three viruses was seen in about 90 percent of participants.
The combination vaccine was safe, producing only a faint rash in about 60 percent of the participants, according to Fauci...
Dengue Fever Vaccine Trials Clear First Hurdle
Jessica Berman
January 24, 2013
Human trials of an experimental dengue fever vaccine have just concluded, and the experimental compound looks promising in offering protection against the complex mosquito-borne illness that afflicts millions of people living in tropical and sub-tropical regions...
...
The U.S. government-funded trial was small, involving 112 healthy men and women between the ages of 18 and 50. The purpose was to see whether the experimental vaccine, made up of live but weakened viruses, was both safe and stimulated an antibody response against all four dengue types.
Researchers at Johns Hopkins School of Public Health in Baltimore, Maryland formulated four different versions of the combination vaccine, and tested a separate vaccine in each of four groups of 20 study participants. All of the dengue vaccines produced an antibody response. But one experimental compound, called TV003, induced an immune response against all four dengue viruses in 45 percent of participants. And an immune response to three viruses was seen in about 90 percent of participants.
The combination vaccine was safe, producing only a faint rash in about 60 percent of the participants, according to Fauci...